A doença de Steinert, também conhecida como distrofia miotônica tipo 1, é uma doença muscular caracterizada por miotonia e por danos em múltiplos órgãos que combina vários graus de fraqueza muscular, arritmia e/ou distúrbios de condução cardíaca, catarata, danos endócrinos, distúrbios do sono e calvície.
Introdução
O que você precisa saber de cara
A distrofia miotônica de Steinert é uma doença genética que afeta os músculos e outros órgãos do corpo. Ela costuma causar fraqueza muscular, dificuldade de relaxar os músculos após contraí-los (miotonia), problemas no coração, catarata e cansaço excessivo. Os primeiros sinais podem surgir em qualquer fase da vida, desde o nascimento até a fase adulta. A doença não possui um medicamento específico fornecido por protocolo do SUS, mas a rede pública oferece procedimentos de atendimento em reabilitação para doenças raras.
A doença de Steinert, também conhecida como distrofia miotônica tipo 1, é uma doença muscular caracterizada por miotonia e por danos em múltiplos órgãos que combina vários graus de fraqueza muscular, arritmia e/ou distúrbios de condução cardíaca, catarata, danos endócrinos, distúrbios do sono e calvície.
O que está sendo pesquisado
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 40 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 143 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.
Curadoria gene-doença
fontes oficiaisDystrophia myotonica 1
A muscular disorder characterized by myotonia, muscle wasting in the distal extremities, cataract, hypogonadism, defective endocrine functions, male baldness and cardiac arrhythmias.
Medicamentos e terapias
Mecanismo: Sodium channel alpha subunit blocker
Variantes genéticas (ClinVar)
204 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 218 variantes classificadas pelo ClinVar.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Distrofia miotônica de Steinert
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 14 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
14 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
38 ensaios clínicos encontrados, 19 ativos.
Publicações mais relevantes
A systems perspective on rare diseases: integrating human phenotype ontology with the Anukta framework of Ayurveda.
Rare diseases, though individually uncommon, collectively affect millions and remain among the most underdiagnosed and poorly managed conditions in conventional healthcare. Ayurveda, with its systems approach and emphasis on Dosha imbalance, offers a complementary lens to interpret such unlisted conditions, known as Anukta Vyadhi. Human Phenotype Ontology (HPO) that catalogs 10,610 phenotypes across 12,678 rare diseases can be used to bridge modern phenotype vocabularies and Ayurvedic classifications. This study explores whether integrating the Anukta framework can enable meaningful assessment of rare diseases in Ayurveda clinical settings. A curated list of 140 Nanatmaja Vikara (NV)-Vata (80), Pitta (40), and Kapha (20) was mapped to HPO terms, preserving the semantic context of Ayurvedic descriptions. Noteworthy, 128 of NV phenotypes mapped to 199 HPO terms. Over 7200 rare diseases had representation of Nanatmaja Vikara. Vata-linked features were the most enriched (4786), followed by Pitta (465) and Kapha (240). 1349 of diseases showed dual Dosha involvement and 360 of all three. Seizures, short stature, and ptosis were most prevalent features of nV; gastroesophageal reflux, fever, and abnormal skin blistering of nP; and obesity, lethargy, and pallor of nK. Detailed case interpretation of Steinert Myotonic Dystrophy, Syndromic Diarrhea and Alstrom Syndrome revealed association with Vata-Kapha, Vata-Pitta, and Tridosha features respectively. This integration of Anukta framework with structured ontologies provides a practical pathway for understanding rare diseases for management in Ayurveda clinics and integrative decision-making when biomedical options are limited.
Reproductive choices and intrafamilial communication in neurogenetic diseases with different self-estimated severities.
Low uptake of presymptomatic testing and medically assisted reproduction in families impacted by neurogenetic diseases prompted us to investigate how reproductive options are considered and whether there is a relationship with perceived severity of the disease. We hypothesised that self-estimated severity would influence opinion on reproductive options and that prenatal/preimplantation diagnosis would be a motivation to inform relatives about their risk. We invited people impacted by neurogenetic diseases to evaluate the severity of their familial disease using analogic visual scales and to answer questionnaires about reproductive choices and intrafamilial communication. We compared answers between diseases and with the perceived severity of each disease. We analysed 562 questionnaires. Participants were impacted by Huntington disease (n=307), spinocerebellar ataxias (n=114), Steinert myotonic dystrophy (n=82) and amyotrophic lateral sclerosis/frontotemporal dementia (n=59). Self-estimated severity differed between pathologies (p<0.0001). Overall, participants considered prenatal diagnosis (78.0±34.4 out of 100) and preimplantation diagnosis (75.2±36.1 out of 100) justified more than termination of pregnancy (68.6±38.5 out of 100). They were less in favour of gamete donation (48.3±39.8 out of 100) or pregnancy abstention (43.3±40.3 out of 100). The greater the perceived severity of the disease, the more reproductive options were considered justified, except for gamete donation. Prenatal/preimplantation diagnosis was a motivation to inform relatives for only 55.3% of participants (p=0.01). Self-estimated severity minimally impacts opinions towards reproductive options. Medically assisted reproduction procedures are rarely sought and do not motivate familial communication.
Long term noninvasive ventilation and continuous positive airway pressure in children with neuromuscular diseases in France.
The aim of the study was to describe the characteristics of children with neuromuscular diseases treated with long term noninvasive ventilation or continuous positive airway pressure in France. On June 1st 2019, 387 patients (63% boys, mean age 11.2 ± 5.5 years) were treated with long term noninvasive ventilation/continuous positive airway pressure. Thirty three percent of patients had spinal muscular atrophy, 30% congenital myopathy/dystrophy, 20% Duchenne muscular dystrophy, 7% Steinert myotonic dystrophy, and 9% other neuromuscular diseases. Ninety-four percent of patients were treated with long term noninvasive ventilation and 6% with continuous positive airway pressure. Treatment was initiated electively for 85% of patients, mainly on an abnormal overnight gas exchange recording (38% of patients). Noninvasive ventilation/continuous positive airway pressure was initiated during a respiratory exacerbation in 15% of patients. Mean duration of noninvasive ventilation/continuous positive airway pressure was 3.3 ± 3.1 years. Mean objective long term noninvasive ventilation/continuous positive airway pressure use was 8.0 ± 3.1 h/24. Spinal muscular atrophy, congenital myopathy/dystrophy, and Duchenne muscular dystrophy represented 83% of children with neuromuscular diseases treated with long term noninvasive ventilation in France. Screening for nocturnal hypoventilation was satisfactory as noninvasive ventilation /continuous positive airway pressure was predominantly initiated electively.
Unilateral implantation of a new non-diffractive extended range-of-vision IOL in a young patient with Curschmann-Steinert myotonic dystrophy.
We present the case of a 36-year old Curschmann-Steinert myotonic dystrophy patient with posterior subcapsular cataract that we treated with unilateral implantation of an extended depth of focus intraocular lens to address his wish for spectacle independence at far and intermediate distance. The patient underwent phacoemulsification with subsequent implantation of the AcrySof IQ Vivity IOL (Alcon, Fort Worth, TX, USA) in his left eye. Uncorrected distance visual acuity (UDVA) on the left eye increased from +0.40 logMAR preoperatively to -0.12 logMAR at 3 months postoperatively. At the three months follow-up distance corrected intermediate visual acuity (DCIVA) at 80 cm distance was -0.08 logMAR and DCIVA at 66 cm distance was 0.14 logMAR for the left eye. The defocus curve showed a functional defocus of 2.0 diopters at 0.2 logMAR or better, corresponding to the extended depth of focus. Dysphotopsia evaluation with a Halo & Glare simulator (Eyeland-Design Network GmbH, Vreden, Germany) revealed a very low level of photic phenomena. Unilateral implantation of a new generation, non-diffractive extended depth of focus IOL was well tolerated and provided good functional results for far and intermediate distances. The patient reported a very low level of photic phenomena.
[Pattern macular dystrophy associated with Steinert myotonic dystrophy: A case report].
Publicações recentes
A systems perspective on rare diseases: integrating human phenotype ontology with the Anukta framework of Ayurveda.
Long term noninvasive ventilation and continuous positive airway pressure in children with neuromuscular diseases in France.
Reproductive choices and intrafamilial communication in neurogenetic diseases with different self-estimated severities.
[Pattern macular dystrophy associated with Steinert myotonic dystrophy: A case report].
Unilateral implantation of a new non-diffractive extended range-of-vision IOL in a young patient with Curschmann-Steinert myotonic dystrophy.
📚 EuropePMC25 artigos no totalmostrando 12
A systems perspective on rare diseases: integrating human phenotype ontology with the Anukta framework of Ayurveda.
Journal of Ayurveda and integrative medicineLong term noninvasive ventilation and continuous positive airway pressure in children with neuromuscular diseases in France.
Neuromuscular disorders : NMDReproductive choices and intrafamilial communication in neurogenetic diseases with different self-estimated severities.
Journal of medical genetics[Pattern macular dystrophy associated with Steinert myotonic dystrophy: A case report].
Journal francais d'ophtalmologieUnilateral implantation of a new non-diffractive extended range-of-vision IOL in a young patient with Curschmann-Steinert myotonic dystrophy.
American journal of ophthalmology case reportsLevator palpebrae superioris muscle advancement for steinert myotonic dystrophy eyelid ptosis.
Journal of plastic, reconstructive & aesthetic surgery : JPRASMultiple Pilomatricomas: A Retrospective Study and Literature Review.
The American Journal of dermatopathologyThe relative frequency of common neuromuscular diagnoses in a reference center.
Arquivos de neuro-psiquiatriaNeuromuscular diseases: Diagnosis and management.
Orthopaedics & traumatology, surgery & research : OTSR[Steinert myotonic dystrophy in the emergency department].
Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias[Cardiac involvement in Steinert myotonic dystrophy: Moroccan experience, about 18 cases].
The Pan African medical journalNeurotrophins, cytokines, oxidative parameters and funcionality in Progressive Muscular Dystrophies.
Anais da Academia Brasileira de CienciasAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Distrofia miotônica de Steinert.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Distrofia miotônica de Steinert e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
A doença é causada por alterações genéticas no gene DMPK, responsável pela produção da proteína quinase da miotonina. Ela tem herança autossômica dominante, de modo que uma cópia alterada do gene pode desencadear os sintomas.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
5 publicações do grafo RarasNet (PubMed) · 7 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Distrofia miotônica de Steinert. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/distrofia-miotonica-de-steinert
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Distrofia miotônica de Steinert
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Genética mendeliana
- fonte: OMIM
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Indexação biomédica
- fonte: MeSH (NLM)
- Moléculas estudadas na doença
- fonte: OpenTargets
- Ensaios clínicos
- fonte: ClinicalTrials.gov